Comparative vasoactive therapy for heart failure

Joseph R. Benotti, Jane E. McCue, Joseph S Alpert

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Dopamine and dobutamine increase myocardial contractility by β-adrenergic stimulation. Both agents provide significant support for decompensating congestive heart failure (CHF) patients. At the same time, both agents can have significant adverse effects. In 1981, it was reported that amrinone, a bipyridine derivative, produced hemodynamic changes similar to those of dobutamine. To confirm these results, the hemodynamic and clinical effects of amrinone were compared with those of dopamine and dobutamine in 15 consecutive patients with CHF. Although each drug improved maximal cardiac index to a similar extent, dopamine did not decrease pulmonary artery wedge pressure and caused a greater increase in heart rate. Dobutamine and amrinone conferred similar hemodynamic benefits: cardiac index improved from 2.4 ± 0.2 to 3.4 ± 0.2 liters/min/m2 with dobutamine and from 2.1 ± 0.2 to 3.2 ± 0.2 liters/min/m2 with amrinone. Pulmonary artery wedge pressure decreased similarly: from 19 ± 2 to 13 ± 1 mm Hg with dobutamine and from 18 ± 2 to 12 ± 1 mm Hg with amrinone. Dobutamine and amrinone produced similar modest decreases in mean arterial pressure and increments in heart rate. Dopamine was poorly tolerated; 5 patients developed such severe adverse reactions that this drug was discontinued prematurely. Dobutamine and amrinone were much better tolerated. Although amrinone caused asymptomatic tachycardia (heart rate increase >20% over baseline) in 4 patients, no patient developed an adverse reaction warranting its premature termination.

Original languageEnglish (US)
JournalThe American journal of cardiology
Volume56
Issue number3
DOIs
StatePublished - Jul 22 1985
Externally publishedYes

Fingerprint

Amrinone
Dobutamine
Heart Failure
Dopamine
Pulmonary Wedge Pressure
Heart Rate
Hemodynamics
Therapeutics
Drug-Related Side Effects and Adverse Reactions
Tachycardia
Adrenergic Agents
Arterial Pressure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Comparative vasoactive therapy for heart failure. / Benotti, Joseph R.; McCue, Jane E.; Alpert, Joseph S.

In: The American journal of cardiology, Vol. 56, No. 3, 22.07.1985.

Research output: Contribution to journalArticle

Benotti, Joseph R. ; McCue, Jane E. ; Alpert, Joseph S. / Comparative vasoactive therapy for heart failure. In: The American journal of cardiology. 1985 ; Vol. 56, No. 3.
@article{a9122ffd585e45479c92108b528646e1,
title = "Comparative vasoactive therapy for heart failure",
abstract = "Dopamine and dobutamine increase myocardial contractility by β-adrenergic stimulation. Both agents provide significant support for decompensating congestive heart failure (CHF) patients. At the same time, both agents can have significant adverse effects. In 1981, it was reported that amrinone, a bipyridine derivative, produced hemodynamic changes similar to those of dobutamine. To confirm these results, the hemodynamic and clinical effects of amrinone were compared with those of dopamine and dobutamine in 15 consecutive patients with CHF. Although each drug improved maximal cardiac index to a similar extent, dopamine did not decrease pulmonary artery wedge pressure and caused a greater increase in heart rate. Dobutamine and amrinone conferred similar hemodynamic benefits: cardiac index improved from 2.4 ± 0.2 to 3.4 ± 0.2 liters/min/m2 with dobutamine and from 2.1 ± 0.2 to 3.2 ± 0.2 liters/min/m2 with amrinone. Pulmonary artery wedge pressure decreased similarly: from 19 ± 2 to 13 ± 1 mm Hg with dobutamine and from 18 ± 2 to 12 ± 1 mm Hg with amrinone. Dobutamine and amrinone produced similar modest decreases in mean arterial pressure and increments in heart rate. Dopamine was poorly tolerated; 5 patients developed such severe adverse reactions that this drug was discontinued prematurely. Dobutamine and amrinone were much better tolerated. Although amrinone caused asymptomatic tachycardia (heart rate increase >20{\%} over baseline) in 4 patients, no patient developed an adverse reaction warranting its premature termination.",
author = "Benotti, {Joseph R.} and McCue, {Jane E.} and Alpert, {Joseph S}",
year = "1985",
month = "7",
day = "22",
doi = "10.1016/0002-9149(85)91191-9",
language = "English (US)",
volume = "56",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Comparative vasoactive therapy for heart failure

AU - Benotti, Joseph R.

AU - McCue, Jane E.

AU - Alpert, Joseph S

PY - 1985/7/22

Y1 - 1985/7/22

N2 - Dopamine and dobutamine increase myocardial contractility by β-adrenergic stimulation. Both agents provide significant support for decompensating congestive heart failure (CHF) patients. At the same time, both agents can have significant adverse effects. In 1981, it was reported that amrinone, a bipyridine derivative, produced hemodynamic changes similar to those of dobutamine. To confirm these results, the hemodynamic and clinical effects of amrinone were compared with those of dopamine and dobutamine in 15 consecutive patients with CHF. Although each drug improved maximal cardiac index to a similar extent, dopamine did not decrease pulmonary artery wedge pressure and caused a greater increase in heart rate. Dobutamine and amrinone conferred similar hemodynamic benefits: cardiac index improved from 2.4 ± 0.2 to 3.4 ± 0.2 liters/min/m2 with dobutamine and from 2.1 ± 0.2 to 3.2 ± 0.2 liters/min/m2 with amrinone. Pulmonary artery wedge pressure decreased similarly: from 19 ± 2 to 13 ± 1 mm Hg with dobutamine and from 18 ± 2 to 12 ± 1 mm Hg with amrinone. Dobutamine and amrinone produced similar modest decreases in mean arterial pressure and increments in heart rate. Dopamine was poorly tolerated; 5 patients developed such severe adverse reactions that this drug was discontinued prematurely. Dobutamine and amrinone were much better tolerated. Although amrinone caused asymptomatic tachycardia (heart rate increase >20% over baseline) in 4 patients, no patient developed an adverse reaction warranting its premature termination.

AB - Dopamine and dobutamine increase myocardial contractility by β-adrenergic stimulation. Both agents provide significant support for decompensating congestive heart failure (CHF) patients. At the same time, both agents can have significant adverse effects. In 1981, it was reported that amrinone, a bipyridine derivative, produced hemodynamic changes similar to those of dobutamine. To confirm these results, the hemodynamic and clinical effects of amrinone were compared with those of dopamine and dobutamine in 15 consecutive patients with CHF. Although each drug improved maximal cardiac index to a similar extent, dopamine did not decrease pulmonary artery wedge pressure and caused a greater increase in heart rate. Dobutamine and amrinone conferred similar hemodynamic benefits: cardiac index improved from 2.4 ± 0.2 to 3.4 ± 0.2 liters/min/m2 with dobutamine and from 2.1 ± 0.2 to 3.2 ± 0.2 liters/min/m2 with amrinone. Pulmonary artery wedge pressure decreased similarly: from 19 ± 2 to 13 ± 1 mm Hg with dobutamine and from 18 ± 2 to 12 ± 1 mm Hg with amrinone. Dobutamine and amrinone produced similar modest decreases in mean arterial pressure and increments in heart rate. Dopamine was poorly tolerated; 5 patients developed such severe adverse reactions that this drug was discontinued prematurely. Dobutamine and amrinone were much better tolerated. Although amrinone caused asymptomatic tachycardia (heart rate increase >20% over baseline) in 4 patients, no patient developed an adverse reaction warranting its premature termination.

UR - http://www.scopus.com/inward/record.url?scp=0021797135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021797135&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(85)91191-9

DO - 10.1016/0002-9149(85)91191-9

M3 - Article

C2 - 4025154

AN - SCOPUS:0021797135

VL - 56

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 3

ER -